REBIRTH, OE 8882, project: Transgenic expression of cytidine deaminase (CDD) and multidrug resistance gene 1 (MDR1) to optimise treatment strategies for acute leukemias and the myelodysplastic syndrome (MDS) [...] Dr. Anuhar Chaturvedi, Molecular Therapy, OE 6864, project: Transcriptional control of MN1 target genes Final exam June 2016. Eileen Hübschen (nee Frenzel) GERMANY supervisor: Prof. Dr. Janciauskiene,

city to improve graft survival after allogeneic or xenogeneic transplantation. Advanced gene regulatory and gene editing approaches, ex situ perfusion as well as tissue and organ engineering strategies

Schweitzer N, Vogel A, Kreipe H , Lehmann U : Concordant hypermethylation of intergenic microRNA genes in human hepatocellular carcinoma as new diagnostic and prognostic marker. Int J Cancer 2013; 133(3): [...] Länger F , Kreipe H , Lehmann U : Oncogenic PIK3CA mutations in lobular breast cancer progression. Genes Chromosomes Cancer 2013; 52(1): 69-80 Eminaga O, Hinkelammert R, Abbas M , Titze U, Eltze E, Bettendorf [...] Transplantation 2013; 95(2): 285-292 Hussein K , Granot G, Shpilberg O, Kreipe H : Clinical utility gene card for: familial polycythaemia vera. Eur J Hum Genet 2013; 21(6). doi: 10.1038/ejhg.2012.216. No

(Dr. med.) Thema: „Strahlentherapie des Mamma- und Prostatakarzinoms: Polymorphismen in Kandidaten-Genen der DNA- Doppelstrangbruch-Reparatur und deren Einfluss auf Erkrankungswahrscheinlichkeit, Strahl

So verhält es sich auch bei sogenannten Multi-omics-Daten, die beispielsweise die Gesamtheit aller Gene und Proteine eines Menschen umfassen. Diese Daten können helfen, Krankheiten zu diagnostizieren,

llen Studie zur Rolle der Proteinkinase-C-alpha in der diabetischen Nephropathie in einem murinen Gen-Knock-out-Modell. Seine pädiatrische Ausbildung begann PD Dr. Böhne 2004 im Rahmen des strukturierten

possibility of working in an international environment with interesting projects on the cutting edge of gene therapy, leukemogenesis and vectorology. Please see scientific goals for additional information. For

Associate Chairman, Dep. of Ped. Oncology, Dana-Farber Cancer Institute: ‘Gene therapy in monogenic diseases, a platform for gene editing in the clinic‘ 11.05.2016 - REBIRTH colloquium ( 5 pm c.t., Lecture [...] p.m.,c.t., lecture hall G) Juan A. Bueren, Ph.D., Head of the Hematopoietic Gene Therapy Division, CIEMAT, Madrid, Spain: Gene Therapy and Cell Reprogramming in Fanconi Anemia 21.06.2010, Special lecture [...] Uhr im Hörsaal Q) ‘The future is here! The next generation of AAV vector as a foundation of cell and gene therapeutics of the future’ Prof. Leszek Lisowski, Translational Vectorology Research Unit, Children’s

2003; 13(2): 133-8 Bock O, Serinsöz E, Neusch M, Schlué J, Kreipe H: The Polycythaemia rubra vera-1 gene is constitutively expressed by bone marrow cells and does not discriminate Polycythaemia vera from [...] Marwedel M, Musholt TJ: Frequency of mutations and loss of heterozygosity of the tumor suppressor gene PTEN in sporadic follicular thyroid carcinomas: does PTEN play a role in carcinogenesis? Langenbecks [...] Kreipe HH, Pfeifer GP, Schlegelberger B, Dammann R: Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003; 22(12): 1866-71 Schultheiss D, Badalyan R, Pilatz A, Gabouev

Institute for Toxicology and Experimental Medicine, the Universities of Dresden and Aarhus (Denmark), Gene Center in München, the Institute of Protein Research (Russian Academy of Science), the synchrotron